MagdalenaElzbietaSobieszczykMD
Infectious Disease • New York, NYHIV/AIDS Medicine
Professor, Medicine, Columbia University College of Phys & Surg
Overview of Dr. Sobieszczyk
Dr. Magdalena Sobieszczyk is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 19 years. She also speaks multiple languages, including Polish. She specializes in hiv/aids medicine. She has more than 100 publications and over 500 citings.
Office
622 W 168th St
# 4
New York, NY 10032
Education & Training
Columbia University Mailman School of Public HealthMPH, Epidemiology, 2003 - 2006
New York Presbyterian Hospital (Columbia Campus)Fellowship, Infectious Disease, 2002 - 2005- New York Presbyterian Hospital (Columbia Campus)Chief Residency, Internal Medicine, 2001 - 2002
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1998 - 2001
- HarvardBA, Department of Germanic Languages and Literatures, 1990 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Certifications & Licensure
NY State Medical License 2000 - 2025- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men Start of enrollment: 2009 May 01
- Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants Start of enrollment: 2019 Jul 17
- Join now to see all
Publications & Presentations
PubMed
- 583 citationsAntibody evasion properties of SARS-CoV-2 Omicron sublineages.Sho Iketani, Lihong Liu, Yicheng Guo, Liyuan Liu, Jasper F-W Chan
Nature. 2022-04-01 - 54 citationsResistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.Qian Wang, Zhiteng Li, Jerren Ho, Yicheng Guo, Andre Yanchen Yeh
The Lancet. Infectious Diseases. 2022-12-01 - 406 citationsPhase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.Ann R. Falsey, Magdalena E. Sobieszczyk, Ian Hirsch, Stephanie Sproule, Merlin L. Robb
The New England Journal of Medicine. 2021-09-29
Press Mentions
AstraZeneca COVID-19 Vaccine 74% Effective, Protects Against Asymptomatic DiseaseOctober 1st, 2021- CUIMC Update - Dec. 14, 2020December 14th, 2020
- COVID-19 Vaccine Update: What You Need to KnowNovember 5th, 2020
- Join now to see all
Other Languages
- Polish
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
